サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1472240

色素沈着治療市場：治療タイプ別、疾患タイプ別、エンドユーザー別：世界の機会分析と産業予測、2023～2032年

Hyperpigmentation Treatment Market By Treatment Type, By Disorder Type, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

出版日
ページ情報
英文 270 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
色素沈着治療市場：治療タイプ別、疾患タイプ別、エンドユーザー別：世界の機会分析と産業予測、2023～2032年
出版日: 2024年02月01日
発行: Allied Market Research
ページ情報: 英文 270 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の色素沈着治療市場は、2022年に51億米ドルとなり、2023年から2032年にかけてCAGR7.5％で成長し、2032年までには105億米ドルに達すると予測されています。

色素沈着は、皮膚の特定部位の黒ずみや変色を特徴とする皮膚科学的疾患です。この現象は、皮膚の色を司る色素であるメラニンが過剰に生成され、皮膚に沈着することで起こります。色素沈着の原因は、肝斑、日焼け、炎症後色素沈着、加齢など様々です。色素沈着の効果的な管理には、外用治療、レーザー治療、ケミカルピーリングの使用がしばしば含まれ、症状のさらなる悪化を防ぐために日焼け対策に努めることが多いです。

Hyperpigmentation Treatment Market-IMG1

色素沈着治療市場の成長は、世界の美容基準の変化と高齢者人口の急増に起因しています。近年、美に対する社会的認識が顕著に変化しており、透明感のある均一な肌が重視されるようになっています。その結果、個人はより完璧な肌色を目指すようになり、色素沈着治療に対する需要の高まりに寄与しています。メディアの影響とソーシャル・プラットフォームの普及に後押しされ、進化する美の基準は、シミのない肌が健康と魅力の象徴とみなされる文化を生み出しました。この文化的変化は、人々が皮膚の変色問題に対処し、望ましい美的感覚を獲得するための効果的な解決策を求めるため、色素沈着治療の採用急増につながっています。このように、世界の美の基準の変化は、色素沈着治療市場の成長を促進すると予想されます。

さらに、高齢者人口の急増も市場の成長に大きく寄与すると予想されます。例えば、米国国勢調査局によると、高齢者人口は2020年に5,580万人に達すると報告されています。世界の人口動態が進化を続け、高齢者の割合が増加するにつれて、色素沈着症の発生率はより高くなります。皮膚の黒ずみを特徴とする色素沈着は、高齢者における一般的な皮膚科的関心事であり、多くの場合、日光曝露、加齢に伴う変化、基礎疾患などの要因に起因しています。皮膚の外観を向上させ、色素沈着の不規則性に対処する解決策を求める高齢者人口が、高度で的を絞った色素沈着治療への需要を煽っています。製薬業界やスキンケア業界は、高齢化社会のユニークなニーズに対応するために特別に調整された革新的な製品や治療法を開発してきました。しかし、ケミカルピーリングや光治療に伴う副作用が市場の成長を抑制しています。

色素沈着治療市場は、治療タイプ、疾患タイプ、エンドユーザー、地域によって区分されます。治療タイプ別では、市場は外用剤、フォトセラピー、マイクロダーマブレーションに分類されます。疾患タイプ別では、市場は老人斑、肝斑、その他に分類されます。その他には、炎症後色素沈着、ニキビ跡などがあります。エンドユーザー別では、病院、皮膚科クリニック、その他に分けられます。地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、その他欧州地域）、アジア太平洋（日本、中国、オーストラリア、インド、韓国、その他アジア太平洋）、ラテンアメリカ（ブラジル、コロンビア、アルゼンチン、その他ラテンアメリカ）、中東・アフリカA（GCC、南米、北アフリカ、その他中東・アフリカA地域）で分析されます。

利害関係者にとっての主なメリット

  • 当レポートは、2022年から2032年までの色素沈着治療市場分析の市場セグメント、現在の動向、推定・動向、力学の定量分析を提供し、優勢な色素沈着治療市場機会を特定します。
  • 市場促進要因、市場抑制要因、市場機会に関連する情報とともに市場調査を提供します。
  • ポーターのファイブフォース分析では、利害関係者が利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるよう、バイヤーとサプライヤーの潜在力を明らかにします。
  • 色素沈着治療の市場セグメンテーションを詳細に分析することで、市場機会を見極めることができます。
  • 各地域の主要国は、世界市場への収益貢献度に応じてマッピングされています。
  • 市場プレイヤーのポジショニングは、ベンチマーキングを容易にし、市場プレイヤーの現在のポジションの明確な理解を提供します。
  • 本レポートには、地域別および世界の色素沈着治療市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析が含まれています。

本レポートで可能なカスタマイズ（追加費用とタイムラインに関しましては販売担当へご連絡ください）

  • 規制ガイドライン
  • 顧客の関心に応じた企業プロファイルの追加
  • 国別または地域別の追加分析 - 市場規模と予測
  • 企業プロファイルの拡張リスト
  • 過去の市場データ
  • 主要プレーヤーの詳細（所在地、連絡先、サプライヤー / ベンダーネットワークなどを含む、エクセル形式）

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
    • 主要な影響要因
    • 主要な投資機会
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会

第4章 色素沈着治療市場：治療タイプ別

  • 概要
  • 局所剤
  • 光治療
  • マイクロダーマブレーション

第5章 色素沈着治療市場：疾患タイプ別

  • 概要
  • 老人斑
  • 肝斑
  • その他

第6章 色素沈着治療市場：エンドユーザー別

  • 概要
  • 病院
  • 皮膚科クリニック
  • その他

第7章 色素増量治療市場：地域別

  • 概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • その他欧州
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • その他アジア太平洋
  • ラテンアメリカ
    • ブラジル
    • コロンビア
    • アルゼンチン
    • その他のラテンアメリカ
  • 中東・アフリカ
    • GCC
    • 南アフリカ
    • 北アフリカ
    • その他中東・アフリカ

第8章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング、2022年

第9章 企業プロファイル

  • Episciences Inc
  • Vivier Pharma
  • Pierre Fabre S.A
  • L'Oreal Group
  • Areolase Corporation
  • Lyma
  • Trophy Skin
  • Bio Italica
  • PCA Skin
  • Procter & Gamble
図表

LIST OF TABLES

  • TABLE 01. GLOBAL HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 02. HYPERPIGMENTATION TREATMENT MARKET FOR TOPICAL AGENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. HYPERPIGMENTATION TREATMENT MARKET FOR PHOTO THERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. HYPERPIGMENTATION TREATMENT MARKET FOR MICRODERMABRASION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 06. HYPERPIGMENTATION TREATMENT MARKET FOR AGE SPOT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. HYPERPIGMENTATION TREATMENT MARKET FOR MELASMA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. HYPERPIGMENTATION TREATMENT MARKET FOR OTHER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. GLOBAL HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 10. HYPERPIGMENTATION TREATMENT MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. HYPERPIGMENTATION TREATMENT MARKET FOR DERMATOLOGICAL CLINICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. HYPERPIGMENTATION TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. HYPERPIGMENTATION TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA HYPERPIGMENTATION TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 18. U.S. HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 19. U.S. HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 20. U.S. HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 21. CANADA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 22. CANADA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 23. CANADA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 24. MEXICO HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 26. MEXICO HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 27. EUROPE HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE HYPERPIGMENTATION TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 31. GERMANY HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 32. GERMANY HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 33. GERMANY HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 34. FRANCE HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 35. FRANCE HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 36. FRANCE HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 37. UK HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 38. UK HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 39. UK HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 40. ITALY HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 41. ITALY HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 42. ITALY HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 43. SPAIN HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 44. SPAIN HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 45. SPAIN HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 46. REST OF EUROPE HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 47. REST OF EUROPE HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 48. REST OF EUROPE HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 49. ASIA-PACIFIC HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 50. ASIA-PACIFIC HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 52. ASIA-PACIFIC HYPERPIGMENTATION TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 53. JAPAN HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 54. JAPAN HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 55. JAPAN HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 56. CHINA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 57. CHINA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 58. CHINA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 59. INDIA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 60. INDIA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 61. INDIA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 62. AUSTRALIA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 63. AUSTRALIA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 64. AUSTRALIA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 65. SOUTH KOREA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH KOREA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH KOREA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 71. LATIN AMERICA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 72. LATIN AMERICA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 73. LATIN AMERICA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 74. LATIN AMERICA HYPERPIGMENTATION TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 75. BRAZIL HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 76. BRAZIL HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 77. BRAZIL HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 78. COLOMBIA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 79. COLOMBIA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 80. COLOMBIA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 81. ARGENTINA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 82. ARGENTINA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 83. ARGENTINA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 84. REST OF LA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 85. REST OF LA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 86. REST OF LA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 87. MIDDLE EAST AND AFRICA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 88. MIDDLE EAST AND AFRICA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 89. MIDDLE EAST AND AFRICA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 90. MIDDLE EAST AND AFRICA HYPERPIGMENTATION TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 91. GCC HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 92. GCC HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 93. GCC HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 94. SOUTH AFRICA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 95. SOUTH AFRICA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 96. SOUTH AFRICA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 97. NORTH AFRICA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 98. NORTH AFRICA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 99. NORTH AFRICA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 100. REST OF MEA HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
  • TABLE 101. REST OF MEA HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022-2032 ($MILLION)
  • TABLE 102. REST OF MEA HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 103. EPISCIENCES INC: KEY EXECUTIVES
  • TABLE 104. EPISCIENCES INC: COMPANY SNAPSHOT
  • TABLE 105. EPISCIENCES INC: PRODUCT SEGMENTS
  • TABLE 106. EPISCIENCES INC: SERVICE SEGMENTS
  • TABLE 107. EPISCIENCES INC: PRODUCT PORTFOLIO
  • TABLE 108. EPISCIENCES INC: KEY STRATERGIES
  • TABLE 109. VIVIER PHARMA: KEY EXECUTIVES
  • TABLE 110. VIVIER PHARMA: COMPANY SNAPSHOT
  • TABLE 111. VIVIER PHARMA: PRODUCT SEGMENTS
  • TABLE 112. VIVIER PHARMA: SERVICE SEGMENTS
  • TABLE 113. VIVIER PHARMA: PRODUCT PORTFOLIO
  • TABLE 114. VIVIER PHARMA: KEY STRATERGIES
  • TABLE 115. PIERRE FABRE S.A: KEY EXECUTIVES
  • TABLE 116. PIERRE FABRE S.A: COMPANY SNAPSHOT
  • TABLE 117. PIERRE FABRE S.A: PRODUCT SEGMENTS
  • TABLE 118. PIERRE FABRE S.A: SERVICE SEGMENTS
  • TABLE 119. PIERRE FABRE S.A: PRODUCT PORTFOLIO
  • TABLE 120. PIERRE FABRE S.A: KEY STRATERGIES
  • TABLE 121. L'OREAL GROUP: KEY EXECUTIVES
  • TABLE 122. L'OREAL GROUP: COMPANY SNAPSHOT
  • TABLE 123. L'OREAL GROUP: PRODUCT SEGMENTS
  • TABLE 124. L'OREAL GROUP: SERVICE SEGMENTS
  • TABLE 125. L'OREAL GROUP: PRODUCT PORTFOLIO
  • TABLE 126. L'OREAL GROUP: KEY STRATERGIES
  • TABLE 127. AREOLASE CORPORATION: KEY EXECUTIVES
  • TABLE 128. AREOLASE CORPORATION: COMPANY SNAPSHOT
  • TABLE 129. AREOLASE CORPORATION: PRODUCT SEGMENTS
  • TABLE 130. AREOLASE CORPORATION: SERVICE SEGMENTS
  • TABLE 131. AREOLASE CORPORATION: PRODUCT PORTFOLIO
  • TABLE 132. AREOLASE CORPORATION: KEY STRATERGIES
  • TABLE 133. LYMA: KEY EXECUTIVES
  • TABLE 134. LYMA: COMPANY SNAPSHOT
  • TABLE 135. LYMA: PRODUCT SEGMENTS
  • TABLE 136. LYMA: SERVICE SEGMENTS
  • TABLE 137. LYMA: PRODUCT PORTFOLIO
  • TABLE 138. LYMA: KEY STRATERGIES
  • TABLE 139. TROPHY SKIN: KEY EXECUTIVES
  • TABLE 140. TROPHY SKIN: COMPANY SNAPSHOT
  • TABLE 141. TROPHY SKIN: PRODUCT SEGMENTS
  • TABLE 142. TROPHY SKIN: SERVICE SEGMENTS
  • TABLE 143. TROPHY SKIN: PRODUCT PORTFOLIO
  • TABLE 144. TROPHY SKIN: KEY STRATERGIES
  • TABLE 145. BIO ITALICA: KEY EXECUTIVES
  • TABLE 146. BIO ITALICA: COMPANY SNAPSHOT
  • TABLE 147. BIO ITALICA: PRODUCT SEGMENTS
  • TABLE 148. BIO ITALICA: SERVICE SEGMENTS
  • TABLE 149. BIO ITALICA: PRODUCT PORTFOLIO
  • TABLE 150. BIO ITALICA: KEY STRATERGIES
  • TABLE 151. PCA SKIN: KEY EXECUTIVES
  • TABLE 152. PCA SKIN: COMPANY SNAPSHOT
  • TABLE 153. PCA SKIN: PRODUCT SEGMENTS
  • TABLE 154. PCA SKIN: SERVICE SEGMENTS
  • TABLE 155. PCA SKIN: PRODUCT PORTFOLIO
  • TABLE 156. PCA SKIN: KEY STRATERGIES
  • TABLE 157. PROCTER & GAMBLE: KEY EXECUTIVES
  • TABLE 158. PROCTER & GAMBLE: COMPANY SNAPSHOT
  • TABLE 159. PROCTER & GAMBLE: PRODUCT SEGMENTS
  • TABLE 160. PROCTER & GAMBLE: SERVICE SEGMENTS
  • TABLE 161. PROCTER & GAMBLE: PRODUCT PORTFOLIO
  • TABLE 162. PROCTER & GAMBLE: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. HYPERPIGMENTATION TREATMENT MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF HYPERPIGMENTATION TREATMENT MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN HYPERPIGMENTATION TREATMENT MARKET
  • FIGURE 04. TOP INVESTMENT POCKETS IN HYPERPIGMENTATION TREATMENT MARKET (2023-2032)
  • FIGURE 05. BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. BARGAINING POWER OF BUYERS
  • FIGURE 07. THREAT OF SUBSTITUTION
  • FIGURE 08. THREAT OF SUBSTITUTION
  • FIGURE 09. COMPETITIVE RIVALRY
  • FIGURE 10. GLOBAL HYPERPIGMENTATION TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE, 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF HYPERPIGMENTATION TREATMENT MARKET FOR TOPICAL AGENT, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF HYPERPIGMENTATION TREATMENT MARKET FOR PHOTO THERAPY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF HYPERPIGMENTATION TREATMENT MARKET FOR MICRODERMABRASION, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE, 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF HYPERPIGMENTATION TREATMENT MARKET FOR AGE SPOT, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF HYPERPIGMENTATION TREATMENT MARKET FOR MELASMA, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF HYPERPIGMENTATION TREATMENT MARKET FOR OTHER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. HYPERPIGMENTATION TREATMENT MARKET, BY END USER, 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF HYPERPIGMENTATION TREATMENT MARKET FOR HOSPITALS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF HYPERPIGMENTATION TREATMENT MARKET FOR DERMATOLOGICAL CLINICS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF HYPERPIGMENTATION TREATMENT MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 23. HYPERPIGMENTATION TREATMENT MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 24. U.S. HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. CANADA HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. MEXICO HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. GERMANY HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. FRANCE HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. UK HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. ITALY HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. SPAIN HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. REST OF EUROPE HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. JAPAN HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. CHINA HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. INDIA HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. AUSTRALIA HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. SOUTH KOREA HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. REST OF ASIA-PACIFIC HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. BRAZIL HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. COLOMBIA HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. ARGENTINA HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. REST OF LA HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. GCC HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 44. SOUTH AFRICA HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 45. NORTH AFRICA HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 46. REST OF MEA HYPERPIGMENTATION TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 47. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 48. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 49. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 50. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 51. COMPETITIVE DASHBOARD
  • FIGURE 52. COMPETITIVE HEATMAP: HYPERPIGMENTATION TREATMENT MARKET
  • FIGURE 53. TOP PLAYER POSITIONING, 2022
目次
Product Code: A186336

The global hyperpigmentation treatment market was valued at $5.1 billion in 2022, and is projected to reach $10.5 billion by 2032, growing at a CAGR of 7.5% from 2023 to 2032. Hyperpigmentation is a dermatological condition characterized by the darkening or discoloration of certain areas of the skin. This phenomenon occurs when an excess amount of melanin, the pigment responsible for skin color, is produced and deposited in the skin. There are various causes of hyperpigmentation such as Melasma, sun exposure, post inflammatory hyperpigmentation, and age factor. Effective management of hyperpigmentation often involves the use of topical treatments, laser therapy, or chemical peels, along with diligent sun protection to prevent further exacerbation of the condition

Hyperpigmentation Treatment Market - IMG1

The hyperpigmentation treatment market growth is attributed to changes in beauty standards globally, and surge in geriatric population. In recent years, there has been a notable shift in societal perceptions of beauty, with an increasing emphasis on clear, even-toned skin. As a result, individuals are now more inclined toward achieving a flawless complexion, contributing to the heightened demand for hyperpigmentation treatments. The evolving beauty standards, fueled by media influence and the pervasive use of social platforms, have created a culture where blemish-free skin is considered a symbol of health and attractiveness. This cultural shift has led to a surge in the adoption of hyperpigmentation treatments as people seek effective solutions to address skin discoloration issues and attain the desired aesthetic. Thus, the change in beauty standards globally is expected to drive the growth of the hyperpigmentation treatment market.

In addition, the surge in geriatric population is expected to significantly contribute to the growth of the market. For instance, according to the U.S. Census Bureau, it was reported that the older population reached 55.8 million in 2020. As the global demographic landscape continues to evolve, with an increasing proportion of elderly individuals, the incidence of hyperpigmentation disorders becomes more prevalent. Hyperpigmentation, characterized by darkened areas of the skin, is a common dermatological concern among the elderly, often attributed to factors such as sun exposure, age-related changes, and underlying medical conditions. The geriatric population seeking solutions to enhance skin appearance and address pigmentation irregularities, has fueled the demand for advanced and targeted hyperpigmentation treatments. The pharmaceutical and skincare industries have developed innovative products and therapies specifically tailored to cater to the unique needs of the aging population. However, side effects associated with the chemical peels and photo therapy restrain the growth of the market.

The hyperpigmentation treatment market is segmented on the basis of treatment type, disorder type, end user, and region. By treatment type, the market is classified into topical agent, photo therapy, and microdermabrasion. By disorder type, the market is divided into age spots, melasma, and others. Others include post-inflammatory hyperpigmentation and acne scars. By end user, it is segregated into hospitals, dermatological clinics, and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), LA (Brazil, Colombia, Argentina, and rest of LA), and MEA (GCC, South Africa, North Africa, and rest of MEA).

Major key players that operate in the hyperpigmentation treatment market are Episciences Inc, Vivier Pharma, Pierre Fabre S.A, L'Oreal Paris, Areolase Corporation, Lyma, Trophy Skin, Bio Italica, PCA Skin and Procter & Gamble. Key players have adopted product launch as a key developmental strategy to improve the product portfolio of the hyperpigmentation treatment market

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hyperpigmentation treatment market analysis from 2022 to 2032 to identify the prevailing hyperpigmentation treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the hyperpigmentation treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global hyperpigmentation treatment market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Treatment Type

  • Topical Agent
  • Photo Therapy
  • Microdermabrasion

By Disorder Type

  • Age Spot
  • Melasma
  • Other

By End User

  • Hospitals
  • Dermatological clinics
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Colombia
    • Argentina
    • Rest Of La
  • Middle East and Africa
    • Gcc
    • South Africa
    • North Africa
    • Rest Of Mea

Key Market Players:

    • Episciences Inc
    • Vivier Pharma
    • Pierre Fabre S.A
    • L'Oreal Group
    • Areolase Corporation
    • Lyma
    • Trophy Skin
    • Bio Italica
    • PCA Skin
    • Procter & Gamble

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
  • 3.4. Market dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: HYPERPIGMENTATION TREATMENT MARKET, BY TREATMENT TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Topical Agent
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Photo Therapy
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Microdermabrasion
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: HYPERPIGMENTATION TREATMENT MARKET, BY DISORDER TYPE

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Age Spot
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Melasma
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Other
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: HYPERPIGMENTATION TREATMENT MARKET, BY END USER

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospitals
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Dermatological clinics
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Others
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: HYPERPIGMENTATION TREATMENT MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by Treatment Type
    • 7.2.3. Market size and forecast, by Disorder Type
    • 7.2.4. Market size and forecast, by End User
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Market size and forecast, by Treatment Type
      • 7.2.5.1.2. Market size and forecast, by Disorder Type
      • 7.2.5.1.3. Market size and forecast, by End User
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Market size and forecast, by Treatment Type
      • 7.2.5.2.2. Market size and forecast, by Disorder Type
      • 7.2.5.2.3. Market size and forecast, by End User
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Market size and forecast, by Treatment Type
      • 7.2.5.3.2. Market size and forecast, by Disorder Type
      • 7.2.5.3.3. Market size and forecast, by End User
  • 7.3. Europe
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by Treatment Type
    • 7.3.3. Market size and forecast, by Disorder Type
    • 7.3.4. Market size and forecast, by End User
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Market size and forecast, by Treatment Type
      • 7.3.5.1.2. Market size and forecast, by Disorder Type
      • 7.3.5.1.3. Market size and forecast, by End User
      • 7.3.5.2. France
      • 7.3.5.2.1. Market size and forecast, by Treatment Type
      • 7.3.5.2.2. Market size and forecast, by Disorder Type
      • 7.3.5.2.3. Market size and forecast, by End User
      • 7.3.5.3. UK
      • 7.3.5.3.1. Market size and forecast, by Treatment Type
      • 7.3.5.3.2. Market size and forecast, by Disorder Type
      • 7.3.5.3.3. Market size and forecast, by End User
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Market size and forecast, by Treatment Type
      • 7.3.5.4.2. Market size and forecast, by Disorder Type
      • 7.3.5.4.3. Market size and forecast, by End User
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Market size and forecast, by Treatment Type
      • 7.3.5.5.2. Market size and forecast, by Disorder Type
      • 7.3.5.5.3. Market size and forecast, by End User
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Market size and forecast, by Treatment Type
      • 7.3.5.6.2. Market size and forecast, by Disorder Type
      • 7.3.5.6.3. Market size and forecast, by End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by Treatment Type
    • 7.4.3. Market size and forecast, by Disorder Type
    • 7.4.4. Market size and forecast, by End User
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Market size and forecast, by Treatment Type
      • 7.4.5.1.2. Market size and forecast, by Disorder Type
      • 7.4.5.1.3. Market size and forecast, by End User
      • 7.4.5.2. China
      • 7.4.5.2.1. Market size and forecast, by Treatment Type
      • 7.4.5.2.2. Market size and forecast, by Disorder Type
      • 7.4.5.2.3. Market size and forecast, by End User
      • 7.4.5.3. India
      • 7.4.5.3.1. Market size and forecast, by Treatment Type
      • 7.4.5.3.2. Market size and forecast, by Disorder Type
      • 7.4.5.3.3. Market size and forecast, by End User
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Market size and forecast, by Treatment Type
      • 7.4.5.4.2. Market size and forecast, by Disorder Type
      • 7.4.5.4.3. Market size and forecast, by End User
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Market size and forecast, by Treatment Type
      • 7.4.5.5.2. Market size and forecast, by Disorder Type
      • 7.4.5.5.3. Market size and forecast, by End User
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Market size and forecast, by Treatment Type
      • 7.4.5.6.2. Market size and forecast, by Disorder Type
      • 7.4.5.6.3. Market size and forecast, by End User
  • 7.5. Latin America
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast, by Treatment Type
    • 7.5.3. Market size and forecast, by Disorder Type
    • 7.5.4. Market size and forecast, by End User
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Market size and forecast, by Treatment Type
      • 7.5.5.1.2. Market size and forecast, by Disorder Type
      • 7.5.5.1.3. Market size and forecast, by End User
      • 7.5.5.2. Colombia
      • 7.5.5.2.1. Market size and forecast, by Treatment Type
      • 7.5.5.2.2. Market size and forecast, by Disorder Type
      • 7.5.5.2.3. Market size and forecast, by End User
      • 7.5.5.3. Argentina
      • 7.5.5.3.1. Market size and forecast, by Treatment Type
      • 7.5.5.3.2. Market size and forecast, by Disorder Type
      • 7.5.5.3.3. Market size and forecast, by End User
      • 7.5.5.4. Rest Of La
      • 7.5.5.4.1. Market size and forecast, by Treatment Type
      • 7.5.5.4.2. Market size and forecast, by Disorder Type
      • 7.5.5.4.3. Market size and forecast, by End User
  • 7.6. Middle East and Africa
    • 7.6.1. Key market trends, growth factors and opportunities
    • 7.6.2. Market size and forecast, by Treatment Type
    • 7.6.3. Market size and forecast, by Disorder Type
    • 7.6.4. Market size and forecast, by End User
    • 7.6.5. Market size and forecast, by country
      • 7.6.5.1. Gcc
      • 7.6.5.1.1. Market size and forecast, by Treatment Type
      • 7.6.5.1.2. Market size and forecast, by Disorder Type
      • 7.6.5.1.3. Market size and forecast, by End User
      • 7.6.5.2. South Africa
      • 7.6.5.2.1. Market size and forecast, by Treatment Type
      • 7.6.5.2.2. Market size and forecast, by Disorder Type
      • 7.6.5.2.3. Market size and forecast, by End User
      • 7.6.5.3. North Africa
      • 7.6.5.3.1. Market size and forecast, by Treatment Type
      • 7.6.5.3.2. Market size and forecast, by Disorder Type
      • 7.6.5.3.3. Market size and forecast, by End User
      • 7.6.5.4. Rest Of Mea
      • 7.6.5.4.1. Market size and forecast, by Treatment Type
      • 7.6.5.4.2. Market size and forecast, by Disorder Type
      • 7.6.5.4.3. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product mapping of top 10 player
  • 8.4. Competitive dashboard
  • 8.5. Competitive heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Episciences Inc
    • 9.1.1. Company overview
    • 9.1.2. Key executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. Vivier Pharma
    • 9.2.1. Company overview
    • 9.2.2. Key executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. Pierre Fabre S.A
    • 9.3.1. Company overview
    • 9.3.2. Key executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. L'Oreal Group
    • 9.4.1. Company overview
    • 9.4.2. Key executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
    • 9.4.7. Key strategic moves and developments
  • 9.5. Areolase Corporation
    • 9.5.1. Company overview
    • 9.5.2. Key executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
    • 9.5.7. Key strategic moves and developments
  • 9.6. Lyma
    • 9.6.1. Company overview
    • 9.6.2. Key executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
    • 9.6.7. Key strategic moves and developments
  • 9.7. Trophy Skin
    • 9.7.1. Company overview
    • 9.7.2. Key executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
    • 9.7.7. Key strategic moves and developments
  • 9.8. Bio Italica
    • 9.8.1. Company overview
    • 9.8.2. Key executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
    • 9.8.7. Key strategic moves and developments
  • 9.9. PCA Skin
    • 9.9.1. Company overview
    • 9.9.2. Key executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
    • 9.9.7. Key strategic moves and developments
  • 9.10. Procter & Gamble
    • 9.10.1. Company overview
    • 9.10.2. Key executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance
    • 9.10.7. Key strategic moves and developments